Determination of Nabumetone and Its Major Metabolite in Plasma and Tablet Formulations by Reverse-Phase HPLC
- 1 November 1997
- journal article
- pharmaceutical analysis
- Published by Taylor & Francis in Analytical Letters
- Vol. 30 (14) , 2485-2492
- https://doi.org/10.1080/00032719708001759
Abstract
A high performance liquid chromatographic procedure is presented for the determination of nabumetone in pharmaceutical tablets and in plasma. An aliquot of the sample is dissolved in 50% acetonitrile (ACN) containing 4-methoxyacetophenone as an internal standard and chromatographed on a Supelcosil LC-8 (5μ) (150 mm × 4.6 mm i.d.) column. The mobile phase was a mixture of acetonitrile (500 mL), triethylamine (1.5 mL) and glacial acetic acid (8 mL) diluted to 1000 mL, with distilled deionized water. The detection was carried at 270 nm. The method was tested for linearity, recovery and specificity.Keywords
This publication has 4 references indexed in Scilit:
- NabumetoneDrugs, 1988
- Nabumetone kinetics in the young and elderlyThe American Journal of Medicine, 1987
- Nabumetone pharmacokinetics in patients with varying degrees of renal impairmentThe American Journal of Medicine, 1987
- High-performance liquid chromatographic determination of a new anti-inflammatory agent, nabumetone, and its major metabolite in plasma using fluorimetric detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1984